심장 재활 기기 시장 : 제품 유형, 임상 적응증, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Cardiac Rehabilitation Device Market is projected to grow by USD 4.87 billion at a CAGR of 8.50% by 2032.

Cardiac rehabilitation devices are moving from facility-only equipment to connected, data-generating platforms that support supervised exercise, rhythm monitoring, recovery tracking, and risk-factor management after myocardial infarction, revascularization, heart failure, or other cardiovascular events.

The clinical need is substantial. The World Health Organization identifies cardiovascular diseases as the leading cause of death worldwide, accounting for an estimated 17.9 million deaths annually. In the United States, the CDC reports about 805,000 heart attacks each year, underscoring the need for scalable secondary prevention. Evidence-based cardiac rehabilitation is associated with improved functional capacity, better medication adherence, and lower risk of rehospitalization, making devices that enable safe participation increasingly important to health systems and payers.

Transformative Shifts in the Cardiac Rehabilitation Device Landscape

The cardiac rehabilitation device landscape is being reshaped by hybrid care models, remote patient monitoring, and consumer-grade wearables connected to clinical workflows. Hospitals and rehabilitation centers continue to rely on ECG telemetry, ergometers, treadmills, blood pressure monitors, and pulse oximetry, while home-based programs increasingly use connected sensors, mobile applications, and cloud dashboards.

This shift is supported by public health priorities. The American Heart Association and major guideline bodies recognize cardiac rehabilitation as a core component of secondary prevention, yet participation remains below eligible-patient levels in many countries. Device makers are therefore competing on interoperability, patient engagement, reimbursement alignment, cybersecurity, and the ability to document measurable outcomes rather than on hardware performance alone.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is adding cumulative value across the cardiac rehabilitation device ecosystem by converting continuous streams of ECG, activity, heart-rate, blood pressure, and symptom data into actionable risk signals. AI-enabled analytics can support patient triage, personalize exercise intensity, identify adherence barriers, and flag patterns that may require clinician review.

The most credible near-term opportunity is decision support rather than autonomous care. FDA-cleared software functions, validated remote monitoring workflows, and transparent clinical governance are essential because cardiac rehabilitation patients often have complex comorbidities. Vendors that combine AI with explainability, cybersecurity, human oversight, and evidence generation will be better positioned than companies promoting unvalidated automation.

Key Regional Insights

North America remains a leading environment for cardiac rehabilitation device adoption because of mature hospital networks, high cardiovascular procedure volumes, digital health reimbursement pathways, and growing use of remote patient monitoring. The United States is particularly influential due to Medicare coverage for cardiac rehabilitation and intensive cardiac rehabilitation, while Canada benefits from provincial cardiac care programs and expanding virtual rehabilitation pilots.

Europe shows strong demand driven by guideline-based secondary prevention, aging populations, and structured rehabilitation pathways across Germany, France, Italy, Spain, and the United Kingdom. The European Union's medical device regulatory framework raises evidence, clinical evaluation, and post-market surveillance expectations, which can increase compliance costs but also strengthens trust in clinically validated devices.

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia address rising cardiovascular disease burden, urban lifestyle risk factors, aging demographics, and uneven access to specialist rehabilitation. Latin America, led by Brazil and Mexico, is gradually adopting connected rehabilitation models in private networks and tertiary hospitals as noncommunicable disease programs gain priority. The Middle East, particularly GCC markets, is investing in advanced cardiovascular care infrastructure and digital health platforms, while Africa presents long-term need for affordable, durable, and mobile-enabled cardiac rehabilitation solutions where access to center-based programs remains limited.

Key Group Insights

The G7 markets are central to premium cardiac rehabilitation device demand because they combine high cardiovascular procedure volumes, established reimbursement systems, advanced hospital infrastructure, and rigorous clinical evidence expectations. These countries also influence procurement standards for remote monitoring, cybersecurity, interoperability, and electronic health record integration.

The European Union is shaping the competitive environment through Medical Device Regulation requirements, data protection rules, and cross-border emphasis on evidence-based care. BRICS economies are important for broad adoption because of large patient populations, increasing hospital investment, and rising chronic disease burden, although affordability, reimbursement maturity, and specialist access vary widely across members.

ASEAN markets are advancing through private hospital expansion, medical tourism hubs, and government efforts to strengthen noncommunicable disease care. GCC countries are investing in advanced cardiology infrastructure and national digital health platforms, creating opportunities for connected rehabilitation systems. NATO countries overlap substantially with high-income markets where procurement increasingly weighs operational resilience, cybersecurity, supply chain transparency, and device compliance.

Key Country Insights

The United States leads in commercial opportunity due to Medicare-recognized cardiac rehabilitation coverage, large post-acute cardiovascular populations, and fast adoption of remote patient monitoring. Canada emphasizes equitable access across provinces and virtual care expansion, while Mexico and Brazil represent growing Latin American demand where private hospitals, tertiary cardiac centers, and urban care networks often lead adoption.

In Europe, the United Kingdom, Germany, France, Italy, and Spain offer strong clinical foundations for secondary prevention, but purchasing is shaped by national health budgets, health technology assessment, reimbursement rules, and regional service capacity. Russia has demand linked to cardiovascular burden and hospital modernization, though procurement complexity, localization requirements, and geopolitical factors affect supplier strategies.

China and India present major long-term volume opportunities because of large populations, expanding cardiology capacity, and rising cardiovascular risk, but success depends on cost-effective devices, local partnerships, and scalable training models. Japan, South Korea, and Australia favor clinically validated, connected rehabilitation systems aligned with aging populations, advanced cardiology care, strong digital health infrastructure, and high expectations for safety and evidence.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated connected devices that improve access without reducing safety. The strongest strategies combine ECG telemetry, activity monitoring, blood pressure tracking, pulse oximetry, patient education, and clinician dashboards into interoperable workflows that fit hospital, outpatient, and home-based cardiac rehabilitation.

Organizations should invest in randomized evidence, real-world outcomes, and health economic data showing reduced readmissions, improved functional capacity, higher adherence, and better program completion. Partnerships with cardiology groups, payers, rehabilitation networks, and digital health providers can accelerate adoption and support integration into secondary prevention pathways.

A resilient strategy should include cybersecurity-by-design, compliance with FDA and EU MDR expectations, multilingual patient engagement, accessible user interfaces, and tiered product models for high-income and cost-sensitive markets.

Research Methodology

This executive summary is developed from verified secondary research and market intelligence synthesis. Core sources include public health data from the World Health Organization and CDC, cardiovascular guidance from the American Heart Association and European cardiology organizations, regulatory information from the FDA and European Commission, and peer-reviewed evidence on cardiac rehabilitation outcomes.

The research approach evaluates clinical need, care delivery models, reimbursement signals, device categories, regional adoption factors, regulatory pathways, and technology trends. Insights are triangulated across epidemiology, policy, clinical guidelines, procurement behavior, digital health adoption, and published clinical evidence to ensure an evidence-based view of the cardiac rehabilitation device landscape.

Conclusion

The cardiac rehabilitation device landscape is gaining strategic importance as cardiovascular disease burden rises and health systems seek scalable secondary prevention. Demand is shifting toward connected, hybrid, and evidence-backed solutions that extend supervised rehabilitation beyond traditional facilities.

Successful participants will be those that prove clinical value, integrate seamlessly into care pathways, protect patient data, and support equitable access across regions. Artificial intelligence, remote monitoring, and interoperable platforms can accelerate transformation, but durable adoption will depend on validated outcomes, regulatory compliance, and trusted implementation.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cardiac Rehabilitation Device Market, by Product Type

• 7.1. Monitoring Devices
  • 7.1.1. Blood Pressure Monitors
  • 7.1.2. EcG Monitors
  • 7.1.3. Multi-Parameter Monitors
  • 7.1.4. Pulse Oximeters
• 7.2. Rehabilitation Equipment
  • 7.2.1. Arm Ergometer
  • 7.2.2. Cycle Ergometers
  • 7.2.3. Treadmills
• 7.3. Therapeutic Devices
  • 7.3.1. Electrical Stimulation Devices
  • 7.3.2. Respiratory Therapy Devices
  • 7.3.3. Ultrasound Therapy Devices

8. Cardiac Rehabilitation Device Market, by Clinical Indication

• 8.1. Post-Myocardial Infarction
• 8.2. Heart Failure Rehabilitation
• 8.3. Post-Coronary Artery Bypass Graft
• 8.4. Post-Valve Replacement

9. Cardiac Rehabilitation Device Market, by End User

• 9.1. Clinics
  • 9.1.1. Cardiac Rehab Clinics
  • 9.1.2. Physical Therapy Clinics
• 9.2. Home Care Settings
  • 9.2.1. Caregiver-Assisted
  • 9.2.2. Self-Administered
• 9.3. Hospitals
• 9.4. Rehabilitation Centers

10. Cardiac Rehabilitation Device Market, by Distribution Channel

• 10.1. Direct Sales
• 10.2. Distributor Networks
• 10.3. Online/e-commerce Platform

11. Cardiac Rehabilitation Device Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Cardiac Rehabilitation Device Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Cardiac Rehabilitation Device Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. AlivCor Inc.
• 15.3. Bardy Diagnostics, Inc.
• 15.4. Berlin Heart GmbH
• 15.5. BiVACOR Inc.
• 15.6. Boston Scientific Corporation
• 15.7. Cardiac Insight, Inc.
• 15.8. Cardiobridge GmbH
• 15.9. CorInnova, Inc.
• 15.10. CorWave SA
• 15.11. GE HealthCare Technologies Inc.
• 15.12. Getinge AB
• 15.13. Hill-Rom Holdings, Inc.
• 15.14. Jarvik Heart Inc.
• 15.15. Koninklijke Philips N.V.
• 15.16. LivaNova PLC
• 15.17. Medtronic PLC
• 15.18. OSI Systems, Inc.
• 15.19. Supira Medical
• 15.20. Teleflex Incorporated
• 15.21. Terumo Corporation
• 15.22. Xenios AG